A case of vacuolar myopathy during the course of chronic hepatitis C

Functional Neurology

Volumn 21, Issue 3, 2006, Pages 169-171

  Zoccolella, Stefano ^a   Serlenga, Luigi ^b   Amati, Angela ^a   Lavolpe, Vito ^a   Minerva, Nicola ^c   Agremorz, Mohammed ^d   Toscano, Antonio ^d   Lamberti, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Lorenzo Bonomo Hospital   (Italy)

^c Hospital of Canosa   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chronic hepatitis; Hepatitis C virus; Vacuolar myopathy

Indexed keywords

ALPHA2A INTERFERON; CREATINE KINASE; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CELL VACUOLE; CHEMICAL ANALYSIS; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; NEUROLOGIC EXAMINATION; VACUOLAR MYOPATHY;

EID: 37849189309     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hill L, Henry B, Schweikert S, Prevention Practice Committee, American College of Preventive Medicine. Screening for chronic hepatitis C: American College of Preventive Medicine practice policy statement. Am J Prev Med 2005; 28:327-330
2. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005;11:86-94
3. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005;17:447-455
4. Matsuya M, Abe T, Tosaka M et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994;33:806-808
5. Sola P, Galassi G, Merelli E, Ferrari MG, Sorgato P, Ghini M. Detection of HCV-specific sequences in chronic myopathy with hepatitis C: improvement with interferon-alpha 2A therapy. Eur Neurol 1999;42:181-183
6. Villanova M, Caudai C, Sabatelli C et al. Hepatitis C virus infection and myositis: a polymerase chain reaction study. Acta Neuropathol (Berl) 2000;99:271-276
7. Sato T, Takatsu Y, Yamada T et al. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J 2000;64:321-324
8. Ueno Y, Kondo K, Kidokoro N, Kobashi R, Kanaji K, Matsumura T. Hepatitis C infection and polymyositis. Lancet 1995;346:319-320
9. Di Muzio A, Bonetti B, Capasso M et al. Hepatitis C virus infection and myositis: a virus localization study. Neuromuscul Disord 2003;13:68-71
10. Kase S, Shiota G, Fujii Y et al. Inclusion body myositis associated with hepatitis C virus infection. Liver 2001;21:357-360
11. Tsuruta Y, Yamada T, Yoshimura T et al. Inclusion body myositis associated with hepatitis C virus infection. Fukuoka Igaku Zasshi 2001;92:370-376
12. Alexander JA, Huebner CJ. Hepatitis C and inclusion body myositis. Am J Gastroenterol 1996;91:1845-1847
13. Yakushiji Y, Satoh J, Yukitake M et al. Interferon beta-responsive inclusion body myositis in a hepatitis C virus carrier. Neurology 2004;63:587-588
14. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003;27:142-156
15. Gabrielli M, Santarelli L, Serricchio M, Leo D, Pola P, Gasbarrini A. Acute reversible rhabdomyolysis during interferon alpha 2b therapy for hepatitis C. Am J Gastroenterol 2003;98:940
16. Golstein PE, Delforge ML, Deviere J, Marcellin P. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. J Viral Hepat 2004;11:183-186
17. Reinhold U, Hartl C, Hering R, Hoeft A, Kreyser HW. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon a in a malignant melanoma. Lancet 1997;349:540-541
18. Lunemann JD, Kassim N, Zschenderlein R, Zipp F. Rhabdomyolysis during interferon-beta 1a treatment. J Neurol Neurosurg Psychiatry 2002;72:274 [Erratum in J Neurol Neurosurg Psychiatry 2002;73:354]